Reasons for less than two CT being performed were: logistical problems (n = 2); discontinuation of study medication (n = 1) and withdrawal of consent (n = 1).
Five patients were not followed up for reasons of death (n = 2), discontinuation of GT/GTE consumption (n = 2), and heart transplantation (n = 1).
(2) Discontinuation of nephrotoxic drugs: potentially nephrotoxic medications, such as aminoglycosides, vancomycin, amphotericin B, and nonsteroidal anti-inflammatory drugs, should be discontinued before contrast media administration [ 48].
Patient retention is comprised of two main components: 1) discontinuation of study drug, where patients continue study follow-up, and 2) discontinuation from the study, where patients either withdraw their consent to any follow-up or are lost to follow-up.
There were 10 discontinuations, mostly due to adverse events.
AEs were reported as the primary reason for 8/37 discontinuations, generally equal between groups.
A total of 4309 individuals (848 discontinuations) were included and samples varied in size from 30 to 980 individuals.
There were 19 discontinuations, 4 (2%) from the ETN + MTX group and 15 (14.6%) from the DMARD + MTX group and thus 281 patients (93.7%) completed the 16-week study [ 15].
The most common reasons were bleeding complications (67/223 discontinuations; 30.0%) followed by non-bleeding side-effects (54/223; 24.2%), stable sinus rhythm (19/223; 8.5%), and worsening of renal function (18/223; 8.1%).
Of the 74 discontinuations for safety, the majority (n = 47) were for SAEs, although many (n = 27) were for AEs that were not serious.
